O'Brien Patrick's Form 4 filing
Arrowhead Pharmaceuticals, Inc.ARWR · filed Jan 7, 2022
- Accession no.
- 0001209191-22-002599
- Filed
- Jan 7, 2022
- Trade date
- Dec 4, 2020-Jan 5, 2022
- Filing delay
- 399 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $2.01M. It was filed 399 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Brien PatrickCIK 0001627183 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2022 | Common Stock | SSaleDisposed | −12,434 | $60.49F2 | −$752,132.66 | 368,941 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −10,350 | $61.88F3 | −$640,458 | 358,591 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −5,000 | $62.49F4 | −$312,450 | 353,591 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −4,400 | $63.75F5 | −$280,500 | 349,191 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −316 | $64.35 | −$20,334.6 | 348,875 | Direct | |
| Dec 4, 2020 | Common Stock | GGiftDisposed | −800 | $0.00 | $0 | 348,075 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $62.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.09 to $63.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.19 to $64.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.